Literature DB >> 17639441

Total hearing loss and blindness caused by relapsing polychondritis and myelodysplastic syndrome.

Bozena Coha1, Ljubica Fustar-Preradovic, Sandra Sekelj, Alen Sekelj.   

Abstract

Relapsing polychondritis is an autoimmune disease that primarily manifests as cartilaginous tissue destruction. However, the immune impairment may also involve noncartilaginous tissues such as kidneys, blood vessels, etc. The disease may occur as a primary disorder or in association with other diseases. The case of a female patient with concurrent manifestation of myelodysplastic syndrome-refractory anemia with excess blasts, and relapsing polychondritis, is presented. The diagnosis of relapsing polychondritis was established ten months after the diagnosis of myelodysplastic syndrome, when the criteria for the former were met. Total hearing loss and blindness developed soon thereafter.

Entities:  

Mesh:

Year:  2007        PMID: 17639441     DOI: 10.1007/s00405-007-0387-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  15 in total

1.  Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness.

Authors:  R Hall; N Hopkinson; T Hamblin
Journal:  Leuk Res       Date:  2000-01       Impact factor: 3.156

Review 2.  Immunologic abnormalities in myelodysplastic syndromes.

Authors:  T Hamblin
Journal:  Hematol Oncol Clin North Am       Date:  1992-06       Impact factor: 3.722

3.  Bilateral necrotizing scleritis and blindness in the myelodysplastic syndrome presumably due to relapsing polychondritis.

Authors:  K U Loeffler; I W McLean
Journal:  Acta Ophthalmol Scand       Date:  2000-04

Review 4.  Relapsing polychondritis: prospective study of 23 patients and a review of the literature.

Authors:  L P McAdam; M A O'Hanlan; R Bluestone; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

5.  Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis.

Authors:  Jane H Buckner; Megan Van Landeghen; William W Kwok; Laura Tsarknaridis
Journal:  Arthritis Rheum       Date:  2002-01

6.  Relapsing polychondritis associated with monoclonal gammopathy in a patient with myelodysplastic syndrome.

Authors:  S S Banerjee; D P Morris; M P Rothera; R C Routledge
Journal:  J Laryngol Otol       Date:  2001-06       Impact factor: 1.469

7.  Relapsing polychondritis--report of ten cases.

Authors:  J M Damiani; H L Levine
Journal:  Laryngoscope       Date:  1979-06       Impact factor: 3.325

8.  Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes.

Authors:  K Van Besien; G Tricot; R Hoffman
Journal:  Am J Hematol       Date:  1992-05       Impact factor: 10.047

Review 9.  Association of myelodysplastic syndrome and relapsing polychondritis: further evidence.

Authors:  M Hebbar; M Brouillard; E Wattel; M Decoulx; P Y Hatron; B Devulder; P Fenaux
Journal:  Leukemia       Date:  1995-04       Impact factor: 11.528

10.  Bone marrow pathology in relapsing polychondritis: high frequency of myelodysplastic syndromes.

Authors:  L Diebold; G Rauh; K Jäger; U Löhrs
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

View more
  2 in total

Review 1.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Authors:  Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

2.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.